69 GLP-1 RA has been shown to interfere with UPR to protect against NDs
If additional glycemic control is needed, the dose can be increased to 1 mg once weekly after at least four weeks, and further to a maximum of 2 mg once weekly if necessary
The truth is, GLP-1s are not for everyone clinical studies have found that just over 10% of patients do not lose weight on semaglutide, while others cant tolerate certain side effects and have to stop taking the drug
Another potential limitation of a TTE approach is the dichotomization of the MDS-UPDRS, a continuous scale, which can lead to a potential disadvantage of reduced accuracy and pose the question of the variability around the threshold and its acceptability
medication adherence is the most important factor in achieving sustainable results (Polonsky et al., Diabetes Care , 2020)